B-intervention	0	8	Elevated
I-intervention	9	15	plasma
I-intervention	16	24	endoglin
I-intervention	25	26	(
I-intervention	26	31	CD105
I-intervention	31	32	)
O	33	41	predicts
O	42	51	decreased
O	52	60	response
O	61	64	and
O	65	73	survival
O	74	76	in
O	77	78	a
O	79	89	metastatic
O	90	96	breast
O	97	103	cancer
O	104	109	trial
O	110	112	of
O	113	120	hormone
O	121	128	therapy
O	128	129	.

O	130	140	Background
O	141	149	Endoglin
O	150	151	(
O	151	156	CD105
O	156	157	)
O	158	160	is
O	161	162	a
O	163	165	co
O	165	166	-
O	166	174	receptor
O	175	178	for
O	179	182	TGF
O	182	183	-
O	183	187	beta
O	187	188	,
O	189	191	is
O	192	201	expressed
O	202	204	by
O	205	210	human
O	211	219	vascular
O	220	231	endothelial
O	232	237	cells
O	237	238	,
O	239	242	and
O	243	248	plays
O	249	250	a
O	251	256	major
O	257	261	role
O	262	264	in
O	265	277	angiogenesis
O	277	278	.

O	279	288	Materials
O	289	292	and
O	293	300	methods
O	301	313	Pretreatment
O	314	318	EDTA
O	319	325	plasma
O	326	330	from
B-intervention-participants	331	334	224
B-eligibility	335	345	metastatic
I-eligibility	346	352	breast
I-eligibility	353	359	cancer
I-eligibility	360	368	patients
O	369	377	enrolled
O	378	380	in
O	381	382	a
O	383	388	phase
O	389	392	III
O	393	396	2nd
O	396	397	-
O	397	401	line
O	402	409	hormone
O	410	417	therapy
O	418	423	trial
O	424	427	and
B-control-participants	428	430	50
B-control	431	438	control
I-control	439	447	subjects
O	448	452	were
O	453	460	assayed
O	461	464	for
O	465	473	endoglin
O	474	479	using
O	480	482	an
O	483	488	ELISA
O	488	489	.

O	490	497	Results
O	498	501	The
O	502	508	female
O	509	516	control
O	517	522	group
O	523	524	(
O	524	525	n
O	526	527	=
B-control-participants	528	530	50
O	530	531	)
O	532	538	plasma
O	539	547	endoglin
O	548	553	upper
O	554	559	limit
O	560	562	of
O	563	569	normal
O	570	573	was
O	574	581	defined
O	582	584	as
O	585	588	the
O	589	593	mean
O	594	595	+
O	596	597	2
O	598	600	SD
O	601	602	(
O	602	603	8
O	603	604	.
O	604	605	7
O	606	608	ng
O	608	609	/
O	609	611	ml
O	611	612	)
O	612	613	.

O	614	617	The
O	618	624	breast
O	625	631	cancer
O	632	639	patient
B-outcome	640	646	plasma
I-outcome	647	655	endoglin
O	656	659	was
O	660	661	6
O	661	662	.
O	662	664	40
O	665	666	+
O	666	667	/
O	667	668	-
O	669	670	2
O	670	671	.
O	671	673	23
O	674	676	ng
O	676	677	/
O	677	679	ml
O	680	681	(
O	681	686	range
O	687	688	3
O	688	689	.
O	689	691	00
O	691	692	-
O	692	694	19
O	694	695	.
O	695	697	79
O	698	700	ng
O	700	701	/
O	701	703	ml
O	703	704	)
O	704	705	.

B-outcome	706	714	Elevated
I-outcome	715	721	plasma
I-outcome	722	730	endoglin
I-outcome	731	737	levels
I-outcome	738	742	were
I-outcome	743	751	detected
O	752	754	in
B-iv-bin-abs	755	757	26
O	758	760	of
B-intervention-participants	761	764	224
O	765	773	patients
O	774	775	(
B-iv-bin-percent	775	777	11
I-iv-bin-percent	777	778	.
I-iv-bin-percent	778	779	6
I-iv-bin-percent	779	780	%
O	780	781	)
O	781	782	.

O	783	791	Patients
O	792	796	with
O	797	805	elevated
O	806	812	plasma
O	813	821	endoglin
O	822	825	had
O	826	827	a
O	828	835	reduced
B-outcome	836	844	clinical
I-outcome	845	852	benefit
I-outcome	853	857	rate
O	858	859	(
O	859	861	CR
O	862	863	+
O	864	866	PR
O	867	868	+
O	869	875	Stable
O	875	876	)
O	877	878	(
B-iv-bin-percent	878	880	15
O	881	883	vs
O	883	884	.
B-cv-bin-percent	885	887	42
I-cv-bin-percent	887	888	%
O	888	889	)
O	890	891	(
O	891	892	P
O	893	894	=
O	895	896	0
O	896	897	.
O	897	899	01
O	899	900	)
O	901	903	to
O	904	911	hormone
O	912	919	therapy
O	919	920	.

B-outcome	921	924	TTP
O	925	928	was
O	929	936	shorter
O	937	940	for
O	941	949	patients
O	950	954	with
O	955	963	elevated
O	964	970	plasma
O	971	979	endoglin
O	979	980	,
O	981	984	but
O	985	988	did
O	989	992	not
O	993	998	reach
O	999	1010	statistical
O	1011	1023	significance
O	1024	1025	(
O	1025	1026	P
O	1027	1028	=
O	1029	1030	0
O	1030	1031	.
O	1031	1032	2
O	1032	1033	)
O	1033	1034	.

O	1035	1043	Patients
O	1044	1048	with
O	1049	1057	elevated
O	1058	1064	plasma
O	1065	1073	endoglin
O	1074	1077	had
O	1078	1087	decreased
B-outcome	1088	1095	overall
I-outcome	1096	1104	survival
O	1105	1106	(
O	1106	1112	median
B-iv-cont-median	1113	1116	645
O	1117	1119	vs
O	1119	1120	.
B-cv-cont-median	1121	1124	947
I-cv-cont-median	1125	1129	days
O	1129	1130	)
O	1131	1132	(
O	1132	1133	P
O	1134	1135	=
O	1136	1137	0
O	1137	1138	.
O	1138	1141	005
O	1141	1142	)
O	1142	1143	.

O	1144	1154	Conclusion
O	1155	1163	Elevated
O	1164	1176	pretreatment
O	1177	1183	plasma
O	1184	1192	endoglin
O	1193	1199	levels
O	1200	1209	predicted
O	1210	1213	for
O	1214	1223	decreased
O	1224	1232	clinical
O	1233	1240	benefit
O	1241	1244	and
O	1245	1246	a
O	1247	1254	shorter
O	1255	1262	overall
O	1263	1271	survival
O	1272	1274	in
O	1275	1285	metastatic
O	1286	1292	breast
O	1293	1299	cancer
O	1300	1308	patients
O	1309	1316	treated
O	1317	1321	with
O	1322	1325	2nd
O	1325	1326	-
O	1326	1330	line
O	1331	1338	hormone
O	1339	1346	therapy
O	1346	1347	.
